Hualan Biological EngineeringInc Asset Resilience Ratio
Hualan Biological EngineeringInc asset resilience ratio. Hualan Biological EngineeringInc (002007) has an Asset Resilience Ratio of 14.68% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See operational self-sufficiency of Hualan Biological EngineeringInc to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Hualan Biological EngineeringInc (2014–2024)
Asset resilience ratio of Hualan Biological EngineeringInc from 2014 to 2024. This chart shows how Hualan Biological EngineeringInc's Asset Resilience Ratio has changed over time. Read 002007 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Hualan Biological EngineeringInc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Hualan Biological EngineeringInc (002007) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.39 Billion | 14.68% |
| Total Liquid Assets | CN¥2.39 Billion | 14.68% |
Asset Resilience Insights
- Moderate Liquidity: Hualan Biological EngineeringInc has 14.68% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Hualan Biological EngineeringInc Industry Peers by Asset Resilience Ratio
Compare Hualan Biological EngineeringInc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Hualan Biological EngineeringInc Asset Resilience Ratio by Year (2014–2024)
Hualan Biological EngineeringInc asset resilience ratio by year from 2014 to 2024. The table below shows the annual Asset Resilience Ratio data for Hualan Biological EngineeringInc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 11.58% | CN¥1.89 Billion ≈ $276.28 Million |
CN¥16.31 Billion ≈ $2.39 Billion |
-1.55pp |
| 2023-12-31 | 13.13% | CN¥2.11 Billion ≈ $309.47 Million |
CN¥16.11 Billion ≈ $2.36 Billion |
-2.94pp |
| 2022-12-31 | 16.07% | CN¥2.37 Billion ≈ $346.71 Million |
CN¥14.74 Billion ≈ $2.16 Billion |
-6.97pp |
| 2021-12-31 | 23.05% | CN¥2.66 Billion ≈ $389.10 Million |
CN¥11.54 Billion ≈ $1.69 Billion |
-6.70pp |
| 2020-12-31 | 29.75% | CN¥2.99 Billion ≈ $436.95 Million |
CN¥10.04 Billion ≈ $1.47 Billion |
-0.68pp |
| 2019-12-31 | 30.43% | CN¥2.31 Billion ≈ $337.65 Million |
CN¥7.58 Billion ≈ $1.11 Billion |
-0.88pp |
| 2018-12-31 | 31.31% | CN¥2.03 Billion ≈ $297.48 Million |
CN¥6.49 Billion ≈ $950.14 Million |
+6.80pp |
| 2017-12-31 | 24.51% | CN¥1.28 Billion ≈ $187.19 Million |
CN¥5.22 Billion ≈ $763.75 Million |
-3.52pp |
| 2016-12-31 | 28.03% | CN¥1.30 Billion ≈ $190.76 Million |
CN¥4.65 Billion ≈ $680.51 Million |
+2.17pp |
| 2015-12-31 | 25.86% | CN¥1.04 Billion ≈ $152.16 Million |
CN¥4.02 Billion ≈ $588.47 Million |
-0.67pp |
| 2014-12-31 | 26.53% | CN¥1.00 Billion ≈ $146.33 Million |
CN¥3.77 Billion ≈ $551.62 Million |
-- |
About Hualan Biological EngineeringInc
Hualan Biological Engineering Inc. researches, develops, produces, and commercializes blood products, vaccines, and genetic engineering products in China and internationally. The company offers human serum albumin to treat blood loss trauma, shock caused by burns, intracranial pressure and persistent, liver cirrhosis, and kidney disease; edema for hypoproteinemia, neonatal hyperbilirubinemia, car… Read more